Get the Stockscreener App
51.85
0.88%
0.3739
Cytokinetics Inc stock is traded at $51.85, with a volume of 315.16K.
It is up +0.88% in the last 24 hours and down -8.37% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$51.48
Open:
$51.31
24h Volume:
315.16K
Relative Volume:
0.28
Market Cap:
$6.10B
Revenue:
$3.13M
Net Income/Loss:
$-545.28M
P/E Ratio:
-9.3938
EPS:
-5.52
Net Cash Flow:
$-401.27M
1W Performance:
+0.83%
1M Performance:
-8.37%
6M Performance:
-20.43%
1Y Performance:
+42.99%
1-Day Range:
$50.88
$52.03
1-Week Range:
$50.53
$52.37
52-Week Range:
$30.68
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Resul - GuruFocus.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Position Increased by Harbor Capital Advisors Inc. - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com
Robert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics CEO Robert Blum sells $258,150 in stock - Investing.com
Cytokinetics CEO Robert Blum sells $258,150 in stock By Investing.com - Investing.com UK
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com
abrdn plc Trims Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics EVP Malik Fady Ibraham sells $378,930 in stock By Investing.com - Investing.com Australia
Cytokinetics director Wendall Wierenga sells shares worth $232,617 - Investing.com India
Cytokinetics EVP Malik Fady Ibraham sells $378,930 in stock - Investing.com
Cytokinetics director Wendall Wierenga sells shares worth $232,617 By Investing.com - Investing.com UK
Cytokinetics, Incorporated Announces Presentations At the 23 Annual HFSA Scientific Meeting - Marketscreener.com
HEART FAILURE (HF) WITH REDUCED EJECTION FRACTION (HFREF) - openPR
Moody Aldrich Partners LLC Sells 23,174 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics' SWOT analysis: aficamten's promise drives stock outlook - Investing.com
Cytokinetics to Announce Third Quarter Results on November 6, 2024 - StockTitan
Possible Bearish Signals With Cytokinetics Insiders Disposing Stock - Simply Wall St
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat
Cytokinetics stock sees no change as Mizuho reiterates Outperform rating after aficamten update - Investing.com Canada
Cytokinetics EVP sells $395,554 in stock By Investing.com - Investing.com South Africa
Cytokinetics retains buy rating, stock target with positive outlook By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ:CYTK) Given Buy Rating at Needham & Company LLC - MarketBeat
Cytokinetics EVP sells $395,554 in stock - Investing.com
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 7,300 Shares of Stock - MarketBeat
Is Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day - The Manila Times
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Cetera Investment Advisers - MarketBeat
From amoeboid myosin to unique targeted medicines for a genetic cardiac disease - Frontiers
Cytokinetics CEO sells $278k in company stock - Investing.com India
Cytokinetics CEO sells $278k in company stock By Investing.com - Investing.com Australia
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells 5,000 Shares of Stock - MarketBeat
SG Americas Securities LLC Cuts Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Inc (CYTK) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Cytokinetics shares target lifted, holds buy on upcoming R&D event By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ:CYTK) Shares Gap Up Following Analyst Upgrade - MarketBeat
Cytokinetics (NASDAQ:CYTK) Price Target Raised to $120.00 - MarketBeat
Verde Servicos Internacionais S.A. Purchases Shares of 36,250 Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
The Manufacturers Life Insurance Company Buys 20,206 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Shares Up 5.2% - MarketBeat
Morgan Stanley Downgrades Cytokinetics (CYTK) - MSN
Cytokinetics to Host Investor & Analyst Day on October 16, 2024 - EIN News
Cytokinetics EVP sells over $380k in company stock By Investing.com - Investing.com Australia
Cytokinetics EVP sells over $380k in company stock - Investing.com India
Ghisallo Capital Management LLC Makes New Investment in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics shares maintain Buy rating from H.C. Wainwright after trial data - Investing.com India
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO |
Nov 01 '24 |
Sale |
51.63 |
5,000 |
258,150 |
397,456 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):